



## Plenary II

# COVID-19 Pandemic and Vaccines in Hong Kong



### Professor Ivan F.N. HUNG

MBChB (Bristol), MD (HK), FRCP (Lon, Edin), FHKCP, FHKAM (Med) PDiplD (HK)

*Clinical Professor, Chief of the Division of Infectious Diseases, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong.*

Professor Ivan Fan Ngai HUNG is currently Ru Chien and Helen Lieh Endowed Professor in Health Sciences Pedagogy, Professor of Medicine and Assistant Dean (Admissions), Chief of the Division of Infectious Diseases, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, and Honorary Consultant in Queen Mary Hospital, Hong Kong. Professor Hung has published more than 240 international peer reviewed original articles, including research articles in the Lancet, the Lancet Infectious Diseases and the Clinical Infectious Diseases. His research interest includes influenza, SARS-CoV-2 and other respiratory virus antiviral treatment and vaccinology.

Since December 2019, the Covid-19 pandemic has caused unprecedented morbidity and mortality, resulting in more than 120 million confirmed cases, 2.7 million deaths and affected 192 countries. This pandemic of the century has once again reminded us of the importance of infection control measures, and research in the development of antiviral and vaccines against the emerging infectious diseases. Various institutes, governments and pharmaceuticals have worked together to develop an effective COVID-19 vaccine. In fact, more than 80 COVID-19 vaccines are currently under clinical trials. Never in the human history has a vaccine development been completed within 1 year. In this lecture, I will discuss the latest update in the clinical management of COVID-19 and the characteristics of the various COVID-19 vaccine platforms in Hong Kong.